

Consolidated Financial Result Digest FY2026/3 4Q

(Fiscal Year Ended March 31, 2026)

Taiyo Holdings Co., Ltd.
(4626: Prime Market of Tokyo Stock Exchange)
Apr. 30, 2026




Any information incorporated in this document is not intended for the purposes of soliciting the purchase or sale of equity share of the Company. All the descriptions and projections are based on the Company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The Company will neither assume nor compensate any loss of anybody resulting from decisions based on information provided here.

Our Business Segments

Electronics

Developing, manufacturing, purchasing and selling chemicals that used in printed circuit boards (PCB) and other electronic components



Medical and Pharmaceuticals

Manufacturing and marketing ethical pharmaceuticals, contract development and manufacturing organization (CDMO), manufacturing and selling dental prosthetics



ICT and Sustainability

Businesses included ICT, fine chemicals, energy, and food, etc.



FY2026/3 4Q Overview

Electronics

- Net sales increased by 17% year on year on a cumulative basis
<Reasons related to cumulative YoY>
Sales volume increased, mainly for PKG and rigid products.
 - PKG products: + Supported by strong demand stemming from the growing use of AI, sales volume increased, mainly for dry film products for memory applications.
 - Rigid products: + Sales volume increased, mainly for automotive and smartphone products.
 - Fluctuations in demand for certain end products led to a decrease in demand for our product, and sales volume of display (white dry film) products decreased.
 - Foreign exchange Effects: - The appreciation of the yen had a negative impact on business results.
Average exchange rate: <FY2026/3> 150.9 JPY/USD
<FY2025/3> 152.5 JPY/USD

Medical and Pharmaceuticals

- Net sales increased by 16% year on year on a cumulative basis
<Reasons related to cumulative YoY>
Contract manufacturing business saw an increase in contract volume.
 - Contract manufacturing business: + The start of full-scale contract manufacturing for new customers resulted in an increase in contract volume.
 - + Contract volume from exiting customers increased.
 - Manufacturing and marketing business: + Sale volume increased due to higher demand in line with supply shortages of drugs with the same indications at other companies.
 - + Sales increased due to the upward revision of drug prices for certain products following the NHI drug price revision.
 - Sales volume decreased for items subject to the elective care scheme, which was implemented from October 2024.

Company

- Expression of opinion in support of the planned commencement of the tender offer for company shares by KJ005 Co., Ltd. and neutral position regarding tendering of shares

Consolidated Financial Results Summary


Unit : JPY Million	① 2025/3 4Q Cumulative Result	② 2026/3 4Q Cumulative Result	②-① YoY	(②-①)/① % of Changes	③ 2026/3 Full-Year Forecast (Announced on Feb. 4)	②/③ % of Progress
Net Sales	119,010	137,851	18,841	16%	133,000	104%
Operating Income	22,067	32,529	10,462	47%	29,600	110%
Ordinary Income	21,577	32,244	10,667	49%	29,100	111%
Net Income	10,780	24,011	13,231	123%	20,100	119%
Exchange rate of JPY/USD	152.5	150.9	(1.6)		*	
EBITDA	31,709	41,225	9,515	30%	38,200	108%
Operating Income Margin	19%	24%			22%	
EBITDA Margin	27%	30%			29%	

* 1Q to 3Q actual results: 149.3 JPY/USD 4Q forecast (announced at the beginning of 2026/3) : 145.0 JPY/USD

Trend of Yearly Performance

Yearly trend of Net Sales and Operating Income

Unit : JPY Billion



* JPY/USD exchange rate : Assumed value for FY2027/3 150.0 JPY/USD


Performance by Segment

Cumulative Net Sales, Operating Income and EBITDA

		①	②	②-①	(②-①)/①	③	②/③
Unit : JPY Million		2025/3 4Q Cumulative Result	2026/3 4Q Cumulative Result	YoY	% of Changes	2026/3 Full-Year Forecast (Announced on Feb.4)	% of Progress
Electronics	Net Sales	81,703	95,285	13,582	17%	91,100	105%
	Operating Income	21,458	29,177	7,718	36%	26,500	110%
	Operating Income Margin	26%	31%			29%	
	EBITDA	25,139	32,973	7,833	31%	30,200	109%
	EBITDA Margin	31%	35%			33%	
Medical and Pharmaceuticals	Net Sales	31,558	36,490	4,932	16%	35,400	103%
	Operating Income	2,049	5,063	3,014	147%	4,600	110%
	Operating Income margin	6%	14%			13%	
	EBITDA	7,061	8,943	1,881	27%	8,600	104%
	EBITDA Margin	22%	25%			24%	
ICT and Sustainability	Net Sales	5,749	6,075	326	6%	-	-
	Operating Income	262	(95)	(357)	(136%)	-	-
	Operating Income Margin	5%	(2%)			-	-
Company Expense	Operating Income / Loss	(1,703)	(1,616)	86		-	-

Trend of Quarterly Performance Net Sales and Operating Income

Unit : JPY Million



BS- Comparison with the Previous Term

Unit : JPY Million

	2025/3	2026/3	Changes		2025/3	2026/3	Changes
Cash and Deposits	44,903	43,203	(1,699)	Notes and Account Payable	8,505	9,501	996
Accounts Receivables* ¹	27,896	34,317	6,420	Short Term Borrowings* ³	17,634	15,754	(1,879)
Inventory* ²	21,345	21,653	308	Long Term Borrowings	46,888	41,098	(5,790)
Others	3,862	3,939	76	Others	16,015	19,816	3,800
Total Current Assets	98,008	103,115	5,106	Total Liabilities	89,043	86,170	(2,873)
Tangible Fixed Assets	67,638	70,501	2,862	Shareholders Equity	94,011	100,983	6,972
Intangible Fixed Assets	16,341	14,465	(1,875)	Accumulated Other Comprehensive Income	8,962	14,761	5,799
Investments and Other Assets	10,034	13,846	3,811	Non-Controlling Interest	4	12	7
Total Fixed Assets	94,014	98,813	4,798	Total Net Assets	102,978	115,757	12,779
Total Assets	192,022	201,928	9,905	Total Liabilities and Net Assets	192,022	201,928	9,905
				Equity to Asset Ratio	53.6%	57.3%	3.7%

*1 Accounts Receivables : Notes Receivable + Accounts Receivable-Trade + Contract Asset


*2 Inventories : Merchandise and Finished Goods + Work in Process + Raw Materials and Supplies

*3 Short-Term Borrowings : Short-Term Borrowings + Long-Term Borrowings Scheduled to Be Repaid within One Year


Trend of Yearly ROE and ROIC

- ✓ Compared to FY2025/3, ROE in FY2026/3 increased due to the rise in net income, and ROIC in FY2026/3 also improved due to the increase in operating income and the decrease in interest-bearing debt.

ROE (Return on Equity)*1



ROIC (Return on invested Capital Equity)*1



*1 ROE : Net income attributable to shareholders of the parent company / Average equity capital during the fiscal year

ROIC : Net operating income after tax / Average of (Balance of interest-bearing debt + Total equity) during the fiscal year

*2 Risk-free rate (Japan government bond yield) of 2.4%

+ Taiyo Holdings' β value of 1.0-1.1 \times risk premium of 5-6%

Planned Commencement of Tender Offer for the Company Shares

- ✓ At the Board of Directors meeting held on March 31, 2026, we resolved to express our support for the tender offer for our shares by KJ005 Co., Ltd. and to leave the decision of whether to tender their shares up to our shareholders.

Overview of the Transaction*

Tender Offeror	KJ005 Co., Ltd. (investment funds managed by KKR)
Tender Offer Period	21 business days in principle (Planned to be commenced in early October 2026)
Tender Offer Price	4,750 yen per common share
Minimum shares to be purchased	44,648,100 shares (ownership ratio: 40.12%)
Max shares to be purchased	None

Future Schedule



* For details, please refer to the disclosure dated March 31, 2026 below.

[“Notice Concerning Expression of Opinion in Support of the Planned Commencement of the Tender Offer for Company Shares by KJ005 Co., Ltd. and Neutral Position Regarding Tendering of Shares”](#)

Cash dividends

- ✓ In light of the planned commencement of a tender offer, we resolved at the Board of Directors meeting held on March 31, 2026, to revise our dividend forecast for the fiscal year ended March 2026, and not to pay a year-end dividend for that fiscal year. We also do not expect to declare interim and year-end dividends in the fiscal year ended March 31, 2027.

	Annual cash dividends *			Dividend on Equity ratio	Dividend payout ratio (Consolidated)
	Second quarter-end	Fiscal year-end	Total		
Fiscal year ended March 31, 2025	40.00 yen	150.00 yen	190.00 yen	11.6%	98.4%
Fiscal year ended March 31, 2026	165.00 yen	—	165.00 yen	9.5%	38.2%
Fiscal year ended March 31, 2027 (Forecast)	—	—	—	—	—

* We performed a stock split with effect from December 1, 2025 whereby each of our common stock was divided into two shares. The cash dividends per share for the fiscal year ended March 31, 2026 are presented without reflecting the effect of this stock split.

Acquisition of External Evaluations

- ✓ We have newly recognized as a DX-Certified Company and an Outstanding Corporation for Food Education Initiatives 2026.

DX-Certified Company	Outstanding Corporation for Food Education Initiatives 2026	Health & Productivity Management Outstanding Organization (large enterprise category)
----------------------	---	---



Certification Date	December 1, 2025	April 1, 2026	March 9, 2026
Certification History	Recognized for the first time	Recognized for the first time	for the second consecutive year
Certification Body	Ministry of Economy, Trade and Industry	A public-private food education platform comprising governmental bodies, including the Ministry of Agriculture, Forestry and Fisheries, and private-sector companies	Japan Health Council (“Nippon Kenko Kaigi”), a council established by private organizations in collaboration and with full support from governmental bodies



Electronics

Electronics Terminology


Term	Definition
PCB	<u>P</u> rinted <u>C</u> ircuit <u>B</u> oard
SR	<u>S</u> older <u>R</u> esist, also known as Solder Mask
PKG	Semiconductor <u>P</u> ack <u>a</u> ge
DF	<u>D</u> ry <u>F</u> ilm
BU	<u>B</u> uild- <u>u</u> p

Electronics Product Classification

Group	Category		Type	Remarks
PCB insulating materials	Rigid	Regular	Liquid	<ul style="list-style-type: none"> ▪ SR materials for insulation and surface protection use ▪ Marking, etching and plating materials ▪ Electronic materials etc.
		High end	Liquid/DF	
	PKG		Liquid/DF	
	FPC (Flexible printed circuit board)		Liquid/DF	
	BU		Liquid/DF	
Other related products	Others		Liquid/DF	<ul style="list-style-type: none"> ▪ Conductive paste etc.

Electronics Net Sales by Product Category


Unit : JPY Million




Operating Income Margin

Electronics Net Sales by Sales Area

Unit : JPY Million



Operating Income Margin



Medical and Pharmaceuticals


Medical and Pharmaceutical Terminology

Term	Definition
LLP	<u>L</u> ong <u>L</u> isted <u>P</u> roduct A drug for which the patent or re-examination period has expired, enabling the sale of generic drugs
CDMO	<u>C</u> ontract <u>D</u> evelopment <u>M</u> anufacturing <u>O</u> rganization Organizations contracted to manufacture and develop pharmaceutical formulations
GMP	<u>G</u> ood <u>M</u> anufacturing <u>P</u> ractice Standards for manufacturing control and quality of pharmaceuticals and quasi-drugs

Medical and Pharmaceuticals Net Sales by Company

Unit : JPY Million

4Q Cumulative
YoY **QoQ**





Earnings Forecasts

FY2027/3 Earnings Forecasts Overview

Electronics

- Net sales are expected to increase by 7% from FY2026/3 results. Average exchange rate for FY2027/3 are assumed to be 150.0 JPY/USD.
 - We assume the yen to appreciate by 0.9 yen compared with 150.9 JPY/USD (the actual exchange rate for FY2026/3), which will negatively impact earnings.
 - PKG products: Continued strong demand driven by the spread of AI, sales volumes is expected to increase, mainly for memory-related products.
 - Rigid products (liquid): A moderate increase in demand is expected for automotive-related products. Sales volume is projected to remain at approximately the same level as in the fiscal year ended March 31, 2026, as a result of reviewing our focus product areas.
 - Rigid products (DF): A decrease in sales volume is expected due to an anticipated decline in demand for our display-related products resulting from changes to specifications for final products.
- Operating income is expected to increase by 7% from FY2026/3 results.
 - SGA expenses: R&D expenses and other expenses are expected to increase.

Medical and Pharmaceuticals

- Net sales are expected to increase by 3% from FY2026/3 results.
 - Contract manufacturing business: The contract volume is expected to increase.
 - Manufacturing and marketing business: Drug price for certain products is expected to increase following the NHI drug price revision in April 2026.
- Operating income is expected to decrease by 21% from FY2026/3 results.
 - Contract manufacturing business: A decrease in operating income is expected due to higher cost of sales and selling, general and administrative expenses.
 - Manufacturing and marketing business: An increase in cost of sales and selling, general and administrative expenses is expected, driven mainly by higher raw material prices and other factors.

ICT and Sustainability

- Net sales and operating income are both expected to increase from FY2026/3 results.

Notes Regarding Earnings Forecasts

The forecasts in these materials are based on information available when the results were announced. Because it is hard to calculate reasonable estimates for a steep rise in raw material prices and difficulties in procuring them and other factors accompanying escalating tensions in the Middle East at present, we have not incorporated them in our forecasts. In addition, actual results may differ from the forecasts due to various future factors, including the potential occurrence of additional expenses related to the Tender Offer.

FY2027/3 Full-year Earnings Forecasts

Full-year Earnings Forecasts

Unit : JPY Million

	① FY2026/3*1 Full-year Result			② FY2027/3*2 Full-year Forecast			②-①/① % of Changes		
	Consolidated	Electronics	Medical and Pharmaceuticals	Consolidated	Electronics	Medical and Pharmaceuticals	Consolidated	Electronics	Medical and Pharmaceuticals
Net Sales	137,851	95,285	36,490	146,300	102,200	37,500	6%	7%	3%
Operating Income	32,529	29,177	5,063	34,300	31,300	4,000	5%	7%	(21%)
Ordinary Income	32,244	-	-	33,400	-	-	4%	-	-
Net Income	24,011	-	-	24,100	-	-	0%	-	-
EBITDA	41,225	32,973	8,943	43,200	35,200	8,000	5%	7%	(11%)
Operating Income Margin	24%	31%	14%	23%	31%	11%			
EBITDA Margin	30%	35%	25%	30%	34%	21%			

*1 JPY/USD exchange rate : Actual results for FY2026/3 150.9 JPY

*2 JPY/USD exchange rate : Assumed value for FY2027/3 150.0 JPY

FY2027/3 1st half & 2nd half Earnings Forecasts

1st half Earnings Forecasts FY2027/3

Unit : JPY Million

2nd half Earnings Forecasts FY2027/3

Unit : JPY Million


	FY2026/3 ^{*1}			FY2027/3 ^{*2}			FY2026/3 ^{*1}			FY2027/3 ^{*2}		
	1 st half Result			1 st half Forecast			2 nd half Result			2 nd half Forecast		
	Consolidated	Electronics	Medical and Pharmaceuticals	Consolidated	Electronics	Medical and Pharmaceuticals	Consolidated	Electronics	Medical and Pharmaceuticals	Consolidated	Electronics	Medical and Pharmaceuticals
Net Sales	67,830	46,346	18,451	73,100	51,600	18,300	70,021	48,939	18,039	73,200	50,600	19,200
Operating Income	15,187	13,794	2,426	16,800	15,500	1,800	17,342	15,382	2,637	17,500	15,800	2,200
Ordinary Income	15,078	-	-	16,300	-	-	17,166	-	-	17,100	-	-
Net Income	11,022	-	-	11,800	-	-	12,988	-	-	12,300	-	-
EBITDA	19,477	15,616	4,387	21,100	17,400	3,800	21,747	17,356	4,556	22,100	17,800	4,200
Operating Income Margin	22%	30%	13%	23%	30%	10%	25%	31%	15%	24%	31%	11%
EBITDA Margin	29%	34%	24%	29%	34%	21%	31%	35%	25%	30%	35%	22%

*1 JPY/USD exchange rate : Actual results for FY2026/3 150.9 JPY


*2 JPY/USD exchange rate : Assumed value for FY2027/3 150.0 JPY

Trend of Yearly Capital Investment and Depreciation

Capital Investment*1 Unit : JPY Million



Depreciation*2 Unit : JPY Million



*1 Capital investment: Investment in property, plant and equipment and software

*2 Depreciation: Depreciation of property, plant and equipment and software

*3 Breakdown: <Electronics> 12,190M <Medical and Pharmaceuticals> 1,882M <ICT and Sustainability> 556M <HD> (977M)

The amount is displayed as a negative value due to HD's construction in progress having been transferred to a subsidiary in Electronics Business.

